Baxter International Inc Dossier
Qualitative Analysis
Business overview
Baxter International Inc. is a global medical technology leader that develops, manufactures, and sells an essential portfolio of healthcare products, digital health solutions, and therapies. Following the completion of the divestiture of its Kidney Care segment (Vantive) to Carlyle Group Inc. for $3.8 billion in January 2025, the company has significantly streamlined its operations. Baxter now operates through three primary segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Its core offerings include sterile intravenous (IV) solutions, infusion systems, parenteral nutrition, inhaled anesthetics, generic injectables, and advanced surgical equipment. The company serves hospitals, nursing homes, rehabilitation centers, and patients at home across more than 100 countries.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
The structural separation of the Kidney Care business (Vantive) to establish a leaner, more focused 'New Baxter' centered on higher-margin hospital solutions, connected care, and sterile therapies.
Expected impact: Allows Baxter to reallocate capital and management focus to higher-margin segments like Medical Products and Therapies, Advanced Surgery, and Healthcare Systems and Technologies.
Targeting the global injectable market with a pipeline of over 50 planned launches through 2027, prioritizing ready-to-use premixed injectables to reduce hospital preparation errors.
Expected impact: Aims to capture market share in the $100 billion global injectable market and drive recurring hospital purchasing.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
A multi-year strategic partnership aimed at enhancing patient care through integrated connected care technologies, automating nursing workflows, and reducing administrative burdens.
Terms: Not disclosed
An exclusive distribution agreement to bring MediThinQ's innovative 3D surgical visualization platform, SHIYA, to market, enhancing Baxter's advanced surgery and visualization offerings.
Terms: Not disclosed